A Phase 1 Safety, Tolerability and Pharmacokinetic Study of NOV-1776 Compared to Ketorolac Tromethamine IV in Adult Healthy Volunteers and Gout Patients
This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac tromethamine injection, USP (15mg/mL) comparator in healthy volunteers, including an evaluation of safety, tolerability, and efficacy in gout participants with flare-up.
100 项与 Novilla Pharmaceuticals Inc 相关的临床结果
0 项与 Novilla Pharmaceuticals Inc 相关的专利(医药)
100 项与 Novilla Pharmaceuticals Inc 相关的药物交易
100 项与 Novilla Pharmaceuticals Inc 相关的转化医学